Niclas Björn

<i><scp>ABCB</scp>1</i> Variation Affects Myelosuppression, Progression‐free Survival and Overall Survival in Paclitaxel/Carboplatin‐treated Ovarian Cancer Patients

Niclas Björn, Ingrid Jakobsen Falk, Ignace Vergote et al. · Basic & Clinical Pharmacology & Toxicology · 2018 · 20 citations · Full text

Medicine, Oncology, Pharmacology +16

Whole-genome sequencing and gene network modules predict gemcitabine/carboplatin-induced myelosuppression in non-small cell lung cancer patients

Niclas Björn, Tejaswi V. S. Badam, Rapolas Spalinskas et al. · npj Systems Biology and Applications · 2020 · 15 citations · Full text

Medicine, Genetics, Oncology +17

Genes and variants in hematopoiesis-related pathways are associated with gemcitabine/carboplatin-induced thrombocytopenia

Niclas Björn, Benjamín Sigurgeirsson, Anna Svedberg et al. · The Pharmacogenomics Journal · 2019 · 14 citations · Full text

Medicine, Hematology, Oncology +14

Activation of the μ‐opioid receptor by alicyclic fentanyls: Changes from high potency full agonists to low potency partial agonists with increasing alicyclic substructure

Anna Åstrand, Svante Vikingsson, Ingrid Jakobsen Falk et al. · Drug Testing and Analysis · 2020 · 13 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +15

Combination of tyrosine kinase inhibitors and the MCL1 inhibitor S63845 exerts synergistic antitumorigenic effects on CML cells

Alena Malyukova, Dorina Ujvári, Elham Yektaei‐Karin et al. · Cell Death and Disease · 2021 · 13 citations · Full text

Medicine, Oncology, Pharmacology +17